Activating KRAS and BRAF gene mutations are frequent in CRC, and the downstream MEK1/2-ERK1/2 pathway mediates cytoplasmic retention and inactivation of PPARγ [36]. The gene discussed is KRAS; the disease is colorectal carcinoma.